A Look At COMPASS Pathways (CMPS) Valuation After Phase 3 COMP005 Success In Treatment Resistant Depression

Investor focus on COMPASS Pathways (CMPS) has sharpened after the company reported that its Phase 3 COMP005 trial in treatment resistant depression met its primary endpoint with a statistically significant benefit over placebo.

See our latest analysis for COMPASS Pathways.

The Phase 3 success comes after a period of sharp share price swings, with the stock delivering a 69.49% 1 month share price return and a 43.36% year to date share price return. The 1 year total shareholder return stands at 149.73%, while the 5 year total shareholder return remains negative.

If this kind of rerating in mental health treatments has your attention, it could be a good moment to scan for other specialised healthcare opportunities using the 35 healthcare AI stocks.

With COMPASS Pathways now valued at about US$1.3b and trading at US$9.39 against an average analyst target of US$21.43, the key question is whether the recent optimism leaves the stock undervalued or already pricing in future growth.

Most Popular Narrative: 57.2% Undervalued

Against the last close at $9.39, the most followed narrative pegs COMPASS Pathways' fair value at $21.92, implying a wide gap that hinges on ambitious long term assumptions.

Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.

Read the complete narrative.

Want to see what is built on top of that trial momentum? The core narrative leans on sharp shifts in revenue, margins and future earnings multiples. Curious which numbers need to line up for that $21.92 figure to hold up?

Result: Fair Value of $21.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can change quickly if Phase III results disappoint regulators, or if heavier spending and fresh funding needs further pressure margins and shareholder dilution.

Find out about the key risks to this COMPASS Pathways narrative.

Next Steps

Given the mix of excitement and caution running through this story, act while the details are fresh and carefully weigh the 1 key reward and 5 important warning signs.

Looking for more investment ideas?

If COMPASS Pathways has sharpened your thinking, do not stop here. Use focused stock lists to quickly surface other opportunities that match the way you like to invest.

• Target potential value opportunities by scanning 51 high quality undervalued stocks to find companies that pair strong fundamentals with prices that may not fully reflect the underlying businesses.
• Prioritise financial resilience by reviewing the solid balance sheet and fundamentals stocks screener (44 results) to identify companies with robust finances that can help support operations through different market conditions.
• Spot earlier stage potential by checking the 25 elite penny stocks with strong financials to see where smaller companies with meaningful financial strength could offer a very different risk reward profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com